Summary

This Phase I evaluation of N-MCT in normal volunteers requires sequentially increased doses.
At each dose level, the safety and pharmacokinetic will be measured. This Phase I trial will
have the dose range of N-MCT from 200mg - 1200mg per patient.

Study Design

6 subjects, male & female will receive one dose each of 200 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.

n-methanocarbathymidine
N-MCT

Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

6 subjects, male & female will receive one dose each of 400 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.

n-methanocarbathymidine
N-MCT

Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

8 subjects, males and females, 6 subjects will receive one dose each 800 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.

n-methanocarbathymidine
N-MCT

Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

placebo capsule
Placebo

Two patients in Cohort 3 & 4 will receive placebo capsules which is mannitol filled into size 0 capsules.

8 subjects, males and females, 6 subjects will receive one dose each 1200 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.

n-methanocarbathymidine
N-MCT

Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.

placebo capsule
Placebo

Two patients in Cohort 3 & 4 will receive placebo capsules which is mannitol filled into size 0 capsules.

Primary Outcomes

Measure

The Safety and Tolerability of N-MCT Evaluated By The Sequential Review of Reported Adverse Events (AEs) and Changes from Baseline in Findings on Physical Examination, Vital Sign Measurements, and Safety Laboratory Tests

time frame:
Day 1- Day 7

Secondary Outcomes

Measure

Plasma Concentrations of N-MCT Measured Before and at Multiple Time Points After Oral administration

Urine Concentrations of N-MCT Measured Before and at Multiple Time Points

time frame:
0 - 4, 4 - 8, 8 - 12, and 12 - 24 hours post dose

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria:
Subjects must meet all Inclusion Criteria to be included in the study:
1. Healthy men and women 18 to 45 years of age, inclusive
2. Ability to understand the consent process and study procedures
3. Informed consent obtained and signed
4. Comprehension of the protocol, as determined by the clinic personnel using a series
of questions after explaining the procedures.
5. Subjects agree to be available for all study visits.
6. General good health, no current medical illness or clinically significant abnormal
physical examination findings as determined by study physician investigators
7. Negative past or current history of herpes virus infections, or no current use of
antiviral medications for the treatment of herpes virus infections
8. Negative serum pregnancy test at screening and a negative serum pregnancy test on the
day of admission to the inpatient phase for all female subjects of child bearing
potential.
9. Negative urine toxicology screen for marijuana, cocaine, opiates, amphetamines,
phencyclidine, benzodiazepines, and barbiturates for screening and on the day of
admission to the inpatient phase.
10. Negative urine toxicology screen for nicotine (Cotinine) for screening and on the day
of admission to the inpatient phase.
11. Negative breath alcohol screen and agreement not to consume alcohol for the duration
of the study.
12. Body mass index (BMI) greater than or equal to 18.5 kg/m2 and less than or equal to
29.9 kg/m2 [weight (kg)]/ [height (m)2].
13. Agreement by subjects with reproductive potential to use highly effective
contraception as described in protocol Section 4.1.1.
14. Willingness to avoid strenuous exercise for at least 72 hours prior to initial study
drug administration and during the study to Day 7 visit.
Note: Strenuous physical exercise includes long distance running > 5 km/day, weight
lifting, or any physical activity to which the subject is not accustomed.
Exclusion Criteria:
- Subjects meeting any of the Exclusion Criteria at Baseline will be excluded from
study participation.
1. Medical conditions that preclude participation in the study as determined by the
study physician investigators.
Note: Condition that may preclude participation includes:
1.1. Vital signs that are outside the ranges in the table below, measured after
at least 10 minutes rest:
Blood Pressure (BP) 90-140/55-90 mmHg Pulse Rate (PR) 50 100 beats/min Tympanic
Temperature (T) less than or equal to 37.6ºC Respiration Rate (RR) 12 to 20
breaths/minute
1.2. Current diagnosis of pulmonary disease 1.3. Current diagnosis of asthma,
which has required use of asthma medications within the past year 1.4. History
of or current diagnosis of diabetes mellitus 1.5. Autoimmune disorder, such as
systemic lupus erythematosus, Wegener's granulomatosis, rheumatoid arthritis
1.6. History of malignancy except low-grade skin cancer (i.e., basal cell
carcinoma which has been surgically cured) 1.7. Chronic renal, hepatic, or
pulmonary disease or gastrointestinal tract condition that could interfere with
the absorption of the study drug (e.g., surgical resection of significant
proportions of the stomach or bowel, gastric bypass, gastric banding,
cholecystectomy, irritable bowel syndrome, inflammatory bowel disease) 1.8.
History of cardiac abnormalities including Wolff-Parkinson-White syndrome,
dysrhythmias, or coronary artery disease 1.9. History of prolonged QT interval
2. Clinically significant abnormal electrocardiogram (ECG) at screening in the
judgment of the investigator.
3. Screening laboratory values outside the acceptable low and upper limits unless
deemed NCS by the principal investigator or sub-investigator.
4. Positive serology results for Hepatitis B surface antigen (HBsAg), or hepatitis
C virus (HCV) or human immunodeficiency virus (HIV) antibodies
5. Febrile illness with temperature documented >38°C within 7 days of dosing
6. Pregnancy or breastfeeding
7. Known hypersensitivity or allergic reaction(s) to study drug components,
including ingredients present in the formulation and/or to other nucleoside
analogue antiviral drugs.
8. Have consumed any prohibited products or undergone any prohibited procedure
listed in Table 3 within the indicated time frame.
9. Lack of ability to fully understand the informed consent. This will be
determined by the recruiter/interviewer after explaining the consent and
observing the subject reading the consent.
10. Use of any form of tobacco, including cigarette smoking, pipe smoking, oral
tobacco, for 30 days before screening and for the duration of the study.
11. Any specific condition that, in the judgment of the Investigator, precludes
participation because it could affect subject safety.

Additional Information

Official title

Phase I Trial to Assess the Safety and Pharmacokinetics of a Single Ascending Dose (SAD) of N-Methanocarbathymidine (N-MCT) in Normal Volunteers

Description

This is a Phase 1 trial evaluating the safety and pharmacokinetics of N-MCT administered
orally as a single ascending dose. Healthy male and female (non-pregnant, non-lactating)
subjects ages 18-45, will be consented and allowed to participate in the study if upon
screening they meet the inclusion / exclusion criteria.
Subjects will be enrolled into one of four cohort groups sequentially. Each of the six
subjects in each group will receive doses sequentially within 48 hours between each dose
increase (ie, the second subject in a group will not receive a dose until 48 hours after the
first subject received a dose).
Cohort 1 (6 subjects, male & female) will receive 200 mg, Cohort 2 (6 subjects, male &
female) will receive 400 mg, Cohort 3 (8 subjects, males and females, 2 placebo, 6 treated)
will receive 800 mg and Cohort 4 (8 subjects, males and females, 2 placebo, 6 treated) will
receive 1200 mg of N-MCT.
Each cohort will be completed and the safety data evaluated prior to initiating the next
cohort. All subjects will have plasma and urine samples evaluated for N-MCT.
The PI of the protocol and the IDMC will review safety data (AEs), safety labs, vital signs,
and findings through Day 7 for Cohort 1 before enrolling subjects in Cohort 2. Cohort 2 data
through Day 7 will be reviewed accordingly by the PI and IDMC before enrolling subjects in
Cohort 3. Cohort 3 data through Day 7 will be reviewed by the PI and the IDMC before
enrolling subjects in Cohort 4.
However, prior to dose escalation to a new cohort as described above, GHUCCTS IRB will
review and approve, in expedited review, the IDMC report upon which the decision to escalate
the dose to a new cohort is based.

Trial information was received from ClinicalTrials.gov and was last updated in September 2016.